LaunXP will pay Apollomics $10m upfront within 60 days of the agreement date. Apollomics is also qualified for potential ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

If you have metastatic non-small-cell lungcancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

80% of lung cancer is something called nonsmall cell lung cancer. So where are we today in terms of diagnosis, treatment, and what does the future hold? So to help answer these questions ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.